NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines
NImmune Biopharma has announced a research collaboration with BioTherapeutics, Inc. to advance precision medicines for inflammation and immunology. This partnership will provide NImmune access to BioTherapeutics' preclinical services, regulatory capabilities, and proprietary animal models of disease. The collaboration complements NImmune's existing partnership with NIMML Institute, creating a unique scientific ecosystem for drug development.
This ecosystem has already demonstrated success with the development of NX-13 and its acquisition by AbbVie, Inc. (NYSE: ABBV). The collaboration aims to accelerate the development of NImmune's immunoregulatory drug pipeline, leveraging BioTherapeutics' computational modeling and NIMML Institute's TITAN-X A.I.-powered precision medicine platform.
NImmune Biopharma ha annunciato una collaborazione di ricerca con BioTherapeutics, Inc. per promuovere medicinali di precisione per l'infiammazione e l'immunologia. Questa partnership fornirà a NImmune accesso ai servizi preclinici di BioTherapeutics, alle capacità regolatorie e ai modelli animali proprietari di malattia. La collaborazione integra l'esistente partnership di NImmune con NIMML Institute, creando un ecosistema scientifico unico per lo sviluppo di farmaci.
Questo ecosistema ha già dimostrato successo con lo sviluppo di NX-13 e con la sua acquisizione da parte di AbbVie, Inc. (NYSE: ABBV). La collaborazione mira ad accelerare lo sviluppo della pipeline di farmaci immunoregolatori di NImmune, sfruttando la modellazione computazionale di BioTherapeutics e la piattaforma di medicina di precisione TITAN-X A.I. dell’Istituto NIMML.
NImmune Biopharma ha anunciado una colaboración de investigación con BioTherapeutics, Inc. para avanzar en medicamentos de precisión para la inflamación y la inmunología. Esta asociación proporcionará a NImmune acceso a los servicios preclínicos de BioTherapeutics, a sus capacidades regulatorias y a modelos animales de enfermedad patentados. La colaboración complementa la asociación existente de NImmune con NIMML Institute, creando un ecosistema científico único para el desarrollo de fármacos.
Este ecosistema ya ha demostrado éxito con el desarrollo de NX-13 y su adquisición por parte de AbbVie, Inc. (NYSE: ABBV). La colaboración tiene como objetivo acelerar el desarrollo de la cartera de medicamentos inmunorreguladores de NImmune, aprovechando el modelado computacional de BioTherapeutics y la plataforma de medicina de precisión TITAN-X A.I. del Instituto NIMML.
NImmune Biopharma는 BioTherapeutics, Inc.와 협력을 맺고 염증 및 면역학을 위한 정밀 의약품을 발전시키기로 발표했습니다. 이 파트너십은 NImmune이 BioTherapeutics의 전임상 서비스, 규제 능력 및 독점 동물 질병 모델에 접근할 수 있도록 제공합니다. 이 협력은 NIMML Institute와의 기존 파트너십을 보완하여 의약품 개발을 위한 독창적인 과학 생태계를 만듭니다.
이 생태계는 이미 NX-13의 개발과 AbbVie, Inc. (NYSE: ABBV)의 인수로 성공을 보여주었습니다. 협력은 NImmune의 면역 조절 약물 파이프라인 개발을 가속화하고, BioTherapeutics의 컴퓨터 모델링 및 NIMML Institute의 TITAN-X A.I. 기반 정밀 의약품 플랫폼을 활용하는 것을 목표로 합니다.
NImmune Biopharma a annoncé une collaboration de recherche avec BioTherapeutics, Inc. pour faire avancer des médicaments de précision pour l'inflammation et l'immunologie. Ce partenariat permettra à NImmune d'accéder aux services précliniques de BioTherapeutics, à ses capacités réglementaires et à ses modèles animaux de maladie propriétaires. La collaboration complète le partenariat existant de NImmune avec NIMML Institute, créant ainsi un écosystème scientifique unique pour le développement de médicaments.
Ce système a déjà montré du succès avec le développement de NX-13 et son acquisition par AbbVie, Inc. (NYSE: ABBV). La collaboration vise à accélérer le développement de la pipeline de médicaments immunorégulateurs de NImmune, en s'appuyant sur la modélisation informatique de BioTherapeutics et la plateforme de médecine de précision TITAN-X A.I. de l'Institut NIMML.
NImmune Biopharma hat eine Forschungszusammenarbeit mit BioTherapeutics, Inc. bekannt gegeben, um Präzisionsmedikamente für Entzündung und Immunologie voranzutreiben. Diese Partnerschaft wird NImmune den Zugang zu den präklinischen Dienstleistungen, regulatorischen Fähigkeiten und proprietären Tiermodellen von BioTherapeutics ermöglichen. Die Zusammenarbeit ergänzt die bestehende Partnerschaft von NImmune mit NIMML Institute und schafft ein einzigartiges wissenschaftliches Ökosystem für die Arzneimittelentwicklung.
Dieses Ökosystem hat bereits mit der Entwicklung von NX-13 und dessen Übernahme durch AbbVie, Inc. (NYSE: ABBV) Erfolge gezeigt. Die Zusammenarbeit zielt darauf ab, die Entwicklung der immunregulatorischen Medikamentenpipeline von NImmune zu beschleunigen und dabei das computergestützte Modellieren von BioTherapeutics sowie die TITAN-X A.I.-basierte Plattform für Präzisionsmedizin des NIMML Institute zu nutzen.
- Collaboration with BioTherapeutics provides access to advanced preclinical services and regulatory capabilities
- Partnership complements existing R&D collaboration with NIMML Institute, creating a comprehensive drug development ecosystem
- Previous success demonstrated through development of NX-13 and its acquisition by AbbVie (NYSE: ABBV)
- Access to BioTherapeutics' proprietary animal models of disease, including unique pig models of IBD
- Utilization of TITAN-X A.I.-powered precision medicine platform to enhance drug discovery and development
- None.
Insights
This collaboration between NImmune Biopharma and BioTherapeutics marks a significant step in accelerating precision immunology drug development. By leveraging BioTherapeutics' computational modeling and preclinical services, NImmune gains access to advanced tools for biomarker-driven therapeutic development. The partnership's focus on proprietary animal models, particularly for IBD, could
The integration of AI-powered platforms like TITAN-X further enhances NImmune's capabilities, potentially shortening the time from discovery to clinical testing. This ecosystem approach, which previously contributed to the successful development and acquisition of NX-13 by AbbVie, demonstrates a proven track record that could attract investor interest. However, it's important to note that while this collaboration strengthens NImmune's R&D capabilities, it doesn't guarantee clinical or commercial success for their pipeline products.
The collaboration between NImmune and BioTherapeutics represents a promising approach to tackling complex immunological disorders. By combining NImmune's focus on LANCL immunoregulatory drugs with BioTherapeutics' advanced modeling and preclinical services, there's potential for more targeted and effective therapies. The emphasis on biomarker-driven development is particularly noteworthy, as it aligns with the growing trend towards personalized medicine in immunology.
The partnership's scope, covering diseases like ulcerative colitis, Crohn's disease, psoriasis and lupus, addresses a significant unmet need in the field. The integration of AI-powered platforms and sophisticated animal models could lead to more accurate predictions of drug efficacy and safety, potentially reducing the risk of late-stage clinical failures. However, it's important to remember that the complex nature of immune-mediated diseases means that success is not guaranteed, despite these advanced approaches.
This collaboration positions NImmune Biopharma favorably in the competitive landscape of immunology drug development. The partnership with BioTherapeutics and NIMML Institute creates a unique R&D ecosystem that could potentially accelerate drug development timelines and reduce costs. The success of NX-13 and its acquisition by AbbVie demonstrates the potential commercial viability of this approach.
The focus on precision medicine and biomarker-driven therapies aligns with current market trends and investor interests in the biotech sector. However, it's important to note that while this collaboration enhances NImmune's capabilities, the company still faces significant competition in the immunology space from established pharma companies and other biotechs. Investors should consider that despite the promising approach, drug development remains a high-risk, high-reward endeavor, with success ultimately dependent on clinical trial outcomes and regulatory approvals.
NImmune will leverage BioTherapeutics’ computational and preclinical services to accelerate biomarker-driven development of its LANCL immunoregulatory drug pipeline
Growing scientific ecosystem also includes NIMML Institute’s TITAN-X A.I.-powered precision medicine platform to strengthen NImmune’s capabilities from discovery to successful clinical testing
Dr. Raquel Hontecillas, BioTherapeutics Chief Scientific Officer, stated, “We are excited to collaborate across teams in support of the development of much-needed therapeutics by providing our highly sophisticated computational and preclinical services, including our proprietary efficacy animal models of autoimmune and inflammatory disease. The unique drug development ecosystem created here in
NImmune’s partnership with BioTherapeutics complements an existing R&D partnership with NIMML Institute, creating a unique scientific innovation ecosystem for transdisciplinary teams to collaborate from discovery through various development phases. This ecosystem demonstrated significant clinical and commercial success this year with BioTherapeutics and NIMML Institute having enabled the development of NX-13 and its acquisition by AbbVie, Inc. (NYSE: ABBV).
"The collaboration with BioTherapeutics is a crucial extension of NImmune's innovative R&D ecosystem that is enabling our team to create safer and more effective immunoregulatory therapeutics that address the unmet clinical needs of patients with inflammatory and autoimmune diseases,” said Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune. “Through NImmune’s strategic partnerships with both the NIMML Institute and BioTherapeutics, we have created a best-in-class scientific ecosystem capable of accelerating the pipeline—from A.I.-enabled target discovery and validation using the TITAN-X platform to preclinical animal modeling to clinical testing and ultimately commercialization. The regulatory infrastructure, preclinical resources, and leading proprietary models of disease and pathology developed and honed at BioTherapeutics allow us to focus NImmune’s organizational energy squarely on advancing clinical development of our immunoregulatory therapeutic pipeline."
“We’re proud to enter this strategic partnership, which combines BioTherapeutics’ validated models of inflammatory and autoimmune diseases with our expertise in rapidly translating fundamental scientific discoveries in immunology into safer and more effective medicines for patients with immune-mediated diseases such as ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, asthma, and systemic lupus erythematosus,” continued Dr. Bassaganya-Riera. “We look forward to the ongoing collaboration between BioTherapeutics and NImmune, as well as the NIMML Institute, to significantly accelerate the clinical development of our high-conviction drug candidates.”
About NImmune Biopharma
NImmune is a late-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by a discovery platform that utilizes advanced computational modeling, A.I. and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. The lead product candidate from NImmune’s discovery platform is omilancor, a wholly-owned Phase 3-ready oral, once-daily, gut-restricted, first-in-class therapeutic targeting LANCL2 for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2H’23. Phase 2 proof-of-concept data for omilancor show potential best in class efficacy and safety. For more information, please visit www.NIMMUNEBIO.COM or contact media@nimmunebio.com.
About BioTherapeutics, Inc.
BioTherapeutics, Inc., a clinical-stage biotech company that synergistically combines the power of advanced computational modeling with translational and clinical experimentation to accelerate the development of novel products for precision medicine and health. The company is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905134707/en/
Media:
Alex Jeffrey/Jonathan Warren
Gasthalter & Co.
NImmune@gasthalter.com
212.257.4170
Source: NImmune Biopharma
FAQ
What is the purpose of NImmune Biopharma's collaboration with BioTherapeutics, Inc.?
How does the collaboration with BioTherapeutics complement NImmune's existing partnerships?
What previous success has this scientific ecosystem demonstrated?
What specific resources will NImmune gain access to through this collaboration?
How does this collaboration aim to accelerate NImmune's drug development process?
